Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
03 Oct 2023
bởiStephen Padilla
Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
03 Oct 2023
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
25 Sep 2023
Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.